Update on targeted therapies for clear cell renal cell carcinoma

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 283-289

  Singer, Eric A ^a   Gupta, Gopal N ^a   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

clear cell; mammalian target of rapamycin; renal cell carcinoma; targeted therapy; tyrosine kinase inhibitor; vascular endothelial growth factor; von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; DOVITINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PERIFOSINE; PLACEBO; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIVOZANIB; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL (TOPIC); DIARRHEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEINURIA; QUALITY OF LIFE; REVIEW; STOMATITIS;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; QUALITY OF LIFE;

EID: 79955037961     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834479c0     Document Type: Review

References (49)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. J Am Med Assoc 1999; 281:1628-1631. (Pubitemid 29211773)
3. Hollingsworth JM, Miller DC, DaignaultS, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006; 98:1331-1334. (Pubitemid 44530728)
4. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27:3225-3234.
5. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009; 56:959-971.
6. Singer EA, Bratslavsky G, Linehan WM, et al. Targeted therapies for nonclear renal cell carcinoma. Target Oncol 2010; 5:119-129.
7. The most recent review of targeted therapies for nonclear RCC. NIH. Clinical trials registry. 2010 [cited 2010 November 24]; Available from: http://clinicaltrials.gov/ct2/home.
8. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296. (Pubitemid 34032623)
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
11. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (avoren): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
12. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137-2143.
13. Escudier B, EisenT, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
14. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
15. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
16. Pal SK, Figlin RA. Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol 2010; 5:131-138.
17. Cella D, Yount S, Du H, et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (fksi). J Support Oncol 2006; 4:191-199. (Pubitemid 43890980)
18. Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007; 10:285-293. (Pubitemid 47077253)
19. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-4681.
20. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170 (6 Pt 1):2163-2172. (Pubitemid 37413950)
21. Semenza GL Targeting hif-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-732. (Pubitemid 37328811)
22. Hay N. The akt-mtor tango and its relevance to cancer. Cancer Cell 2005; 8:179-183. (Pubitemid 41317589)
23. RixeO, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8:975-984. (Pubitemid 47629888)
24. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib- refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4462-4468.
25. Bhargava P, Esteves B, Nosov D, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of av-951, a potent and selective VEGFR 1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009; 27:Abstract 5032.
26. Emoto N, Isozaki O, Ohmura E, et al. Basic fibroblast growth factor (fgf-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growth. J Urol 1994; 152 (5 Pt 1):1 626-1631. (Pubitemid 24326331)
27. Angevin E, Lopez J, Pande A, et al. Tk1258 (dovitinib lactate) in metastatic renal cell carcinoma (MRCC) patients refractory to approved targeted therapies: a phase I/II dose finding biomarker study. J Clin Oncol 2009; 27.
28. Cho D, Figlin RA, Flaherty K, et al. A phase II trial of perforsine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors. J Clin Oncol 2009; 27:Abstract 5101.
29. Vogelzang N, Hutson TE, Samlowski W, et al. Phase II study of perifosene in metastatic renal cell carcinoma (RCC) progressing after prior therapy (rx) with a VEGF receptor inhibitor. J Clin Oncol 2009; 27:Abstract 5034.
30. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28:2131-2136.
31. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794-5799.
32. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mtorc1 and mtorc2. J Biol Chem 2008; 283:34495-34499.
33. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual pi3-kinase/ mtor inhibitor nvp-bez235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16:3628-3638.
34. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009; 280:145-153.
35. Qian DZ, Kachhap SK, Collis SJ, et al. Class ii histone deacetylases are associated with vhl-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006; 66:8814-8821. (Pubitemid 44449199)
36. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931. (Pubitemid 46218695)
37. Frederiksen KS, Lundsgaard D, Freeman JA, et al. Il-21 induces in vivo immune activation of nk cells and cd8(+) t cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008; 57:1439-1449.
38. Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26:2034-2039.
39. Kroeger N, Gajda M, Zanow J, et al. Downsizing a tumor thrombus of advanced renal cell carcinoma with neoadjuvant systemic therapy and resulting histopathological effects. Urol Int 2010; 84:479-484.
40. Tan KV, Namdarian B, Costello AJ, et al. Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. Urol Oncol 2009. [Epub ahead of print]
41. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102:692-696.
42. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518-523; discussion 523.
43. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4076-4081.
44. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009; 182:881-886.
45. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-nl as adjuvant treatment for resectable renal cell carcinoma: an eastern cooperative oncology group/intergroup trial. J Clin Oncol 2003; 21: 1 214-1222. (Pubitemid 46606396)
46. Margulis V, Matin SF, Tannir N, et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009; 73:337-341.
47. Kjaer M, Iversen P, Hvidt V, et al. A randomized trial of postoperative radiotherapy versus observation in stage ii and iii renal adenocarcinoma. A study by the copenhagen renal cancer study group. Scand J Urol Nephrol 1987; 21:285-289. (Pubitemid 18030189)
48. Vogelzang NJ, Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010; 28:5017-5019.
49. Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2009; 21:266-271.